Company Filing History:
Years Active: 2023-2024
Title: The Innovative Contributions of Cyrus Hedvat
Introduction
Cyrus Hedvat is a notable inventor based in New York, NY (US). He has made significant contributions to the field of cancer treatment, particularly through his innovative patents. With a total of 2 patents, Hedvat's work focuses on improving therapeutic methods for patients with specific tumor types.
Latest Patents
Hedvat's latest patents revolve around the treatment of LAG-3 positive tumors. The invention provides a method of treating a tumor in a human patient by identifying the patient as having a LAG-3 positive tumor. The treatment involves administering a PD-1 pathway inhibitor, a combination of a PD-1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor. In some cases, the method also includes identifying the patient as having a LAG-3 positive PD-L1 positive tumor. The LAG-3 inhibitor may be an anti-LAG-3 antibody, while the PD-1 pathway inhibitor could be an anti-PD-1 antibody. These methods aim to improve response rates to treatment, showcasing Hedvat's commitment to advancing cancer therapies.
Career Highlights
Cyrus Hedvat is currently associated with Bristol-Myers Squibb Company, where he continues to innovate in the field of oncology. His work has been instrumental in developing new treatment protocols that enhance patient outcomes.
Collaborations
Hedvat collaborates with esteemed colleagues such as James Novotny, Jr. and Nils Lonberg. Their combined expertise contributes to the advancement of cancer treatment methodologies.
Conclusion
Cyrus Hedvat's contributions to cancer treatment through his innovative patents highlight his dedication to improving patient care. His work at Bristol-Myers Squibb Company and collaborations with other experts further emphasize the impact of his inventions in the medical field.